Publications by authors named "Dave Manan Dilipbhai"
Article Synopsis
- Hepatorenal syndrome-acute kidney injury (HRS-AKI) is a serious complication of chronic liver disease that leads to high rates of illness and death, and terlipressin, a vasopressin analog, shows promise in treating it by effectively managing blood pressure and reducing side effects during continuous infusion.
- This study evaluated the safety and effectiveness of administering terlipressin at a continuous rate of 4 mg/day in patients with HRS-AKI, involving 136 participants who were monitored for their response to treatment and side effects.
- Results indicated that 69.1% of patients experienced a reduction in serum creatinine levels, with an average treatment duration of 7.6 days, although 21.
